JP2017513826A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513826A5
JP2017513826A5 JP2016560695A JP2016560695A JP2017513826A5 JP 2017513826 A5 JP2017513826 A5 JP 2017513826A5 JP 2016560695 A JP2016560695 A JP 2016560695A JP 2016560695 A JP2016560695 A JP 2016560695A JP 2017513826 A5 JP2017513826 A5 JP 2017513826A5
Authority
JP
Japan
Prior art keywords
amino acid
group
substituted
composition
aryl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560695A
Other languages
English (en)
Japanese (ja)
Other versions
JP6642887B2 (ja
JP2017513826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023883 external-priority patent/WO2015153761A2/en
Publication of JP2017513826A publication Critical patent/JP2017513826A/ja
Publication of JP2017513826A5 publication Critical patent/JP2017513826A5/ja
Application granted granted Critical
Publication of JP6642887B2 publication Critical patent/JP6642887B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560695A 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック Expired - Fee Related JP6642887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973994P 2014-04-02 2014-04-02
US61/973,994 2014-04-02
PCT/US2015/023883 WO2015153761A2 (en) 2014-04-02 2015-04-01 Macrocyclic peptidomimetics for alpha-helix mimicry

Publications (3)

Publication Number Publication Date
JP2017513826A JP2017513826A (ja) 2017-06-01
JP2017513826A5 true JP2017513826A5 (enExample) 2018-05-17
JP6642887B2 JP6642887B2 (ja) 2020-02-12

Family

ID=54241434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560695A Expired - Fee Related JP6642887B2 (ja) 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック

Country Status (6)

Country Link
US (1) US10294273B2 (enExample)
EP (1) EP3126375B1 (enExample)
JP (1) JP6642887B2 (enExample)
CN (1) CN106604928A (enExample)
CA (1) CA2944651A1 (enExample)
WO (1) WO2015153761A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10827064B2 (en) 2016-06-13 2020-11-03 Google Llc Automated call requests with status updates
KR102397417B1 (ko) 2016-06-13 2022-05-12 구글 엘엘씨 인간 운영자로의 에스컬레이션
WO2018227053A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Non-chromatographic purification of macrocyclic peptides by a resin catch and release
US11524979B2 (en) 2017-06-15 2022-12-13 University Of Washington Macrocyclic polypeptides
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CA3080617A1 (en) 2017-10-27 2019-05-02 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
US11468893B2 (en) 2019-05-06 2022-10-11 Google Llc Automated calling system
US11158321B2 (en) 2019-09-24 2021-10-26 Google Llc Automated calling system
CN114631300B (zh) 2020-03-20 2025-09-23 谷歌有限责任公司 由自动化助理代表人类参与者进行半委托呼叫
US11303749B1 (en) 2020-10-06 2022-04-12 Google Llc Automatic navigation of an interactive voice response (IVR) tree on behalf of human user(s)
WO2023107353A2 (en) * 2021-12-10 2023-06-15 Merck Sharp & Dohme Llc P53 peptidomimetic macrocycles
TW202417465A (zh) 2022-08-23 2024-05-01 日商富士軟片股份有限公司 環肽或其鹽及ｍｄｍｘ抑制劑
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides
US12225158B2 (en) 2022-12-15 2025-02-11 Google Llc System(s) and method(s) for implementing a personalized chatbot
KR20250134670A (ko) 2023-01-16 2025-09-11 암브룩스, 인코포레이티드 항-cd70 항체-약물 접합체
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP1737884B1 (en) * 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
WO2009099677A2 (en) * 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US8343760B2 (en) * 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides
CN102203126A (zh) * 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
JP2012515172A (ja) * 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
AU2010298338A1 (en) * 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
WO2012100176A2 (en) 2011-01-20 2012-07-26 University Of Rochester Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation

Similar Documents

Publication Publication Date Title
JP2017513826A5 (enExample)
FI3694529T3 (fi) Trispesifiset proteiinit ja niiden käyttömenetelmät
ES2387685T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
US10077294B2 (en) Peptide inhibitors of TEAD/YAP-TAZ interaction
RU2018131636A (ru) Новые конъюгаты аманитина
HRP20120598T1 (hr) Stanično permeabilni peptidni inhibitori jnk signalnog transdukcijskog puta
RU2007136026A (ru) Варианты ил-21
JP2019501141A5 (enExample)
MX2020000413A (es) Una vacuna universal basada en neoantigenos de tumor compartidos para prevencion y tratamiento de canceres inestables de microsatelite (msi).
JP2015522264A5 (enExample)
NZ723940A (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
JP2018507689A5 (enExample)
CA2432971A1 (en) Polypeptides
MX2014001675A (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
EA200501197A1 (ru) Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
FI3335725T3 (fi) Pds5a-epitooppeja immuuniteetin indusoijina
CN112739381A (zh) 使用了hsp47的抑制物质的癌转移抑制
EP2545171A4 (en) HJURP PEPTIDES AND VACCINES COMPRISING THEM
AR113982A1 (es) Péptido antagonista de la actividad de la interleucina-15
MX2012011385A (es) Peptidos ect2 y vacunas que los incluyen.
AR128014A1 (es) Polipéptidos de penetración celular (cpp) y su uso en terapia humana
MX2012006770A (es) Peptidos tmem22 y vacunas que incluyen los mismos.
CN106084009A (zh) 人骨肉瘤u2‑os细胞特异性结合多肽及其应用
MXPA02010813A (es) Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.